Insights

Commercial Intelligence for Healthcare Leaders

Operating data, field signal, and research from LiquidSMARTS℠. What we measure in our own practice, what our newsletter tells commercial leaders, and what the field is telling us this week.

Featured Research

July 6, 2026

We Ran the Lab on Ourselves: Five Months of Operating a Consultancy on AI Agents

For five months we ran LiquidSMARTS℠, a healthcare commercial engineering consultancy, on AI agents and recorded everything. Here is what worked, what broke, and the guard each failure produced.

Read the whitepaper

Field Data Reports

Career Economics for Sales Leaders

What sales careers actually pay, what the job actually demands, and why the two numbers explain each other.

July 6, 2026

Same Job, Different Paycheck: What Sales Careers Actually Pay in 2025-26

The range across U.S. sales roles runs from $34K to $705K. Same country, same year, same job title on a business card. Industry choice is the biggest salary decision most reps ever make.

Read the report

July 6, 2026

The Sales Intensity Report: What the Paycheck Doesn't Show

The compensation numbers get the attention. The intensity numbers explain them. Most reps are working harder than ever at a version of the job that was never designed to let them win.

Read the report

The Boomerang Newsletter

What’s Already In The Room

Field signal, mechanic, and move, published on LinkedIn and archived here for MedTech commercial leaders who read after the fact.

September 22, 2026

The Coverage Calendar Belongs in Your Forecast

Soft Q4 often looks like demand failure. It is usually permission failure.

September 7, 2026

Washington Is About to Grade Your Technology on Labor

Over two decades, labor productivity in US clinical care fell 1% while the rest of the service economy rose 55%. Healthcare spent $150 billion a year on IT to buy that gap. When a productivity divergence this large becomes an election issue, every technology gets sorted into two piles.

August 11, 2026

What Q2 2026 Taught MedTech Leaders

Ten large medtech companies reported the June quarter. Nine raised or held full-year guidance. One cut. The difference was not the environment. It was how long it took the building to hear what the field already knew.

July 11, 2026

The MedTech Career: What the Numbers Actually Say

Two medical device reps. Same country, same year, same job title on the business card. One tops out around $220,000. One clears $600,000. Neither is five times better at selling. What separates the floor from the ceiling is position.

May 26, 2026

The CFO's December Problem Is Already in Your Q3 Pipeline

A December 2026 Medicaid work-reporting deadline is already reshaping how hospital CFOs in high-exposure states evaluate every capital purchase. The rep whose ROI case still uses prior-year margins is presenting a number the CFO cannot use.

May 19, 2026

The List Gets Cut Before You Know There Was a List

When two health systems merge, two vendor lists become one. The rationalization process does not ask which product is better. It asks which supplier the combined system cannot afford to lose.

May 5, 2026

The CFO Already Ran the Numbers

The CFO in your next meeting has already seen the Medicaid reconciliation numbers. They have not frozen your deal because the product is wrong. They are running scenarios before they sign off on anything new.

April 19, 2026

The Room Was Already Full

The buyer is not more sophisticated than the rep. The buyer is more current. Those are two different problems, and the information gap between them is free to close.

March 31, 2026

What Q1 2026 Taught Commercial Leaders in MedTech

Three things defined commercial performance in medtech this quarter. None of them were product problems, and none of them close on their own.

March 17, 2026

The Commercial Role Is Not Disappearing. It Is Being Repriced.

AI can generate the deck, draft the business case, and summarize the literature. If that is what your commercial team does, you have a positioning problem, not a technology problem.

March 9, 2026

The Second Proof Architecture

Clinical evidence used to be enough to close an AI deal in healthcare. It no longer is. The teams winning in 2026 have built a second proof architecture for the CIO, the CMIO, and the governance committee.

February 13, 2026

6 Decision-Makers. 6 Definitions of Value. 1 Deal.

Six people sit around the buying committee table. Six completely different filters. Each one can kill your deal with a single objection, and not one of them can approve it alone.

Recent LinkedIn Analysis

Daily Field Signal

Ten recent posts from the daily MedTech commercial intelligence feed. Read the full analysis on LinkedIn.

Oct 9, 2026

Ops shocks do not show up in the CRM as lost deals. They show up as unexplained pipeline drag, unless someone owns the coverage map.

View on LinkedIn →

Oct 8, 2026

Hiring is not ramp. Put the tenure mix on the table before you argue about the number.

View on LinkedIn →

Oct 6, 2026

Most training vendors end the measurement story when the room empties.

View on LinkedIn →

Oct 5, 2026

Medicare put a number on the lab cut: up to 15% per test, starting January 1. ACLA counts 775 tests at the full 15% in 2027.

View on LinkedIn →

Oct 2, 2026

Software now sits on both sides of the claim, and your rep sees the result first: a case that stalls with no clear reason.

View on LinkedIn →

Oct 1, 2026

You are paying for something you did not do, in accounts you did not lose, to people who have never met you.

View on LinkedIn →

Sep 29, 2026

Wednesday, September 30, is the last day a device can receive Breakthrough designation and still qualify for CMS's easier NTAP pathway.

View on LinkedIn →

Sep 25, 2026

Abbott got FDA approval on September 8 for TactiFlex Duo: pulsed field and radiofrequency in one catheter.

View on LinkedIn →

Sep 24, 2026

Siemens Healthineers shows up in more of my network than any other OEM. That is not a brand preference. It is a map of who is in the room when imaging capital is on the table.

View on LinkedIn →

Sep 23, 2026

CMS finalized a rewrite of the TAVR national coverage rules on September 10. Coverage with evidence development is gone for symptomatic severe aortic stenosis. Asymptomatic severe disease stays under CED.

View on LinkedIn →

See the full feed on LinkedIn →

A focused starting point

Start with one leader
and one outcome.

The Leadership Diagnostic examines one leader and the team they run, sets the baseline for the operational outcome that matters most, and defines a development plan with a named owner and a measurement plan.

Explore the diagnostic

Commercial Intelligence for Healthcare Leaders

We Ran the Lab on Ourselves: Five Months of Operating a Consultancy on AI Agents

Career Economics for Sales Leaders

Same Job, Different Paycheck: What Sales Careers Actually Pay in 2025-26

The Sales Intensity Report: What the Paycheck Doesn't Show

What’s Already In The Room

The Coverage Calendar Belongs in Your Forecast

Washington Is About to Grade Your Technology on Labor

What Q2 2026 Taught MedTech Leaders

The MedTech Career: What the Numbers Actually Say

The CFO's December Problem Is Already in Your Q3 Pipeline

The List Gets Cut Before You Know There Was a List

The CFO Already Ran the Numbers

The Room Was Already Full

What Q1 2026 Taught Commercial Leaders in MedTech

The Commercial Role Is Not Disappearing. It Is Being Repriced.

The Second Proof Architecture

6 Decision-Makers. 6 Definitions of Value. 1 Deal.

Daily Field Signal

Start with one leaderand one outcome.

Start with one leader
and one outcome.